Saturday, May 31, 2025

Latest

Moderna Expands Manufacturing Abilities In Spain, Steps Into New Asian Markets

Moderna Inc (NASDAQ: MRNA) is looking to scale up the production of its mRNA vaccines and therapeutics on a global level. The firm this morning announced a significant expansion within Asian markets, following the news last night that the company is expanding its operations in Spain.

In terms of its operations in Spain, the firm last night indicated it has expanded a long-term collaboration agreement that was previously in place. The collaboration, which is with its partner Laboratorios Farmacéuticos Rovi, S.A, will see the expansion of current capacity for the manufacturing of Moderna’s products within the country.

Presently, Rovi operates several facilities near Madrid where Moderna’s vaccines are produced. The new arrangement expands the working agreement between the two firms for a period of ten years. Presently, the arrangement will see the scaling of the manufacturing of COVID-19 vaccines, while in the future the agreement will facilitate the production of future mRNA vaccine candidates. Included in the arrangement is a series of investments that are said to support the purchase of additional equipment for production lines.

Products produced at the facility are currently used within countries outside of the United States.

In terms of Asian markets, the company this morning announced that it will be establishing new subsidiaries within Hong Kong, Taiwan, Singapore and Malaysia which will be used to “support the delivery of mRNA vaccines and therapeutics.” The expansion of the commercial network follows the company scaling the production of its current vaccine, as well as future mRNA vaccines and therapeutics. The drive to expand within Asian markets is a result of the region reportedly bearing “the highest burden of infectious diseases.”

Moderna’s portfolio currently consists of 40 development programs. 25 of these programs are currently in varying stages of clinical trials.

Moderna last traded at $151.12 on the Nasdaq.


Information for this briefing was found via Edgar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

How To Profit From $3300 Gold? An Inside Look At A Massive 300,000 Oz Project | Martino De Ciccio

We’re At The Start of a Great Silver Boom | Ross McElroy & Andy Bowering – Apollo Silver Corp

Equinox Gold Q1 Earnings: When Everything Goes Wrong

Recommended

ESGold Begins Concentration Tests Ahead Of First Production

Sterling Metals Hits 0.21% Copper Over 482.8 Metres In First Drilling At Soo Copper project

Related News

Moderna To Construct Manufacturing Facility In Australia Under New Strategic Partnership

Moderna Inc (NASDAQ: MRNA) is officially going to the land down under. The company late...

Thursday, March 24, 2022, 08:53:32 AM

Internal Moderna Report Tags Elon Musk, Novak Djokovic, and Russell Brand as ‘High Risk’

Moderna (NASDAQ: MRNA), the Boston-based pharmaceutical company known for its mRNA Covid-19 vaccine, has reportedly...

Tuesday, November 28, 2023, 01:06:00 PM

Moderna Shares Jump After Announcing Q4 2021 Earnings, US$19 Billion Advanced Sales

Moderna Inc (Nasdaq: MRNA) announced this morning its Q4 and full-year 2021 earnings. The vaccine manufacturer...

Thursday, February 24, 2022, 10:51:00 AM

Moderna Shares Soar As Company Announces $3 Billion Stock Buyback

Moderna Inc (NASDAQ: MRNA) shares on Wednesday soared as high as 17% after it announced...

Thursday, August 4, 2022, 08:26:43 AM

New COVID Variant Sweeps China, Is North America Next?

Remarkably, the world could be facing another bout with COVID this year, and with negative...

Thursday, May 25, 2023, 07:35:00 AM